secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0000950170-25-099404
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD
-----------------------------------------------------------------------------

- Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.
- Phase 1b 12 mg cohort: mean HbF increased 8.6% (7.6% to 16.2%); 7/16 patients achieved >20% HbF.
- Hemolysis markers improved: indirect bilirubin -37%, LDH -28%, reticulocyte -30%; total hemoglobin +0.9 g/dL.
- Safety: pociredir generally well-tolerated, no drug-related SAEs, all treatment-related AEs Grade 1.
- 20 mg cohort ongoing; data expected by end of 2025; IND for DBA planned Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/0000950170-25-099404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/fulc-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer